Shin S, Branning R, McGinnis M, Shin A, Ho M, Karpyak V
Clin Transl Sci. 2025; 18(3):e70180.
PMID: 40065582
PMC: 11893730.
DOI: 10.1111/cts.70180.
Rosic T, Babe G, Rodrigues M, Dennis B, Perez R, de Oliveira C
PLoS One. 2025; 20(1):e0314296.
PMID: 39775273
PMC: 11709258.
DOI: 10.1371/journal.pone.0314296.
Olawole W, Li G, Zhou Z, Wu Z, Chen Q
Inj Epidemiol. 2024; 11(1):65.
PMID: 39578923
PMC: 11585137.
DOI: 10.1186/s40621-024-00548-8.
Leton N
Cureus. 2024; 16(9):e70313.
PMID: 39463556
PMC: 11512750.
DOI: 10.7759/cureus.70313.
Ghobadi A, Hanna M, Tovar S, Do D, Duan L, Lee M
J Am Coll Emerg Physicians Open. 2024; 5(5):e13236.
PMID: 39430661
PMC: 11486842.
DOI: 10.1002/emp2.13236.
The impact of chiropractic care on prescription opioid use for non-cancer spine pain: protocol for a systematic review and meta-analysis.
Emary P, Corcoran K, Coleman B, Brown A, Ciraco C, DiDonato J
Syst Rev. 2024; 13(1):232.
PMID: 39267131
PMC: 11394937.
DOI: 10.1186/s13643-024-02654-6.
The immunological and pharmacokinetic evaluation of Lipid-PLGA hybrid nanoparticle-based oxycodone vaccines.
Walter D, Bian Y, Hu H, Hamid F, Rostamizadeh K, Vigliaturo J
Biomaterials. 2024; 313:122758.
PMID: 39182328
PMC: 11402561.
DOI: 10.1016/j.biomaterials.2024.122758.
Healthcare expenditures for people with substance use disorders in drug courts compared to their peers in traditional courts.
Montgomery B, Aldridge A, Drawbridge D, Packer I, Vincent G, Rodriguez-Monguio R
Drug Alcohol Depend Rep. 2024; 12:100258.
PMID: 39156655
PMC: 11327541.
DOI: 10.1016/j.dadr.2024.100258.
Adherence to buprenorphine-XR through hybrid telehealth contingency management procedures: a case series.
Gorman J, Lindvig-Springborn A, Lee J, Khazanov G, DePhilippis D
J Subst Use. 2024; 2024:1-6.
PMID: 39055109
PMC: 11271741.
DOI: 10.1080/14659891.2024.2351019.
IUPHAR review - Glucagon-like peptide-1 (GLP-1) and substance use disorders: An emerging pharmacotherapeutic target.
Bruns Vi N, Tressler E, Vendruscolo L, Leggio L, Farokhnia M
Pharmacol Res. 2024; 207:107312.
PMID: 39032839
PMC: 11467891.
DOI: 10.1016/j.phrs.2024.107312.
Implementation outcomes from a pilot study of training probation officers to deliver contingency management for emerging adults with substance use disorders.
Drazdowski T, Kelton K, Hibbard P, McCart M, Chapman J, Castedo de Martell S
J Subst Use Addict Treat. 2024; 166:209450.
PMID: 38960144
PMC: 11392627.
DOI: 10.1016/j.josat.2024.209450.
Using qualitative system dynamics modeling to understand overdose bystander behavior in the context of Connecticut's Good Samaritan Laws and identify effective policy options.
Thompson R, Sabounchi N, Ali S, Heimer R, DOnofrio G, Heckmann R
Harm Reduct J. 2024; 21(1):124.
PMID: 38937759
PMC: 11210010.
DOI: 10.1186/s12954-024-00990-3.
Behavioral and neuronal extracellular vesicle biomarkers associated with nicotine's enhancement of the reinforcing strength of cocaine in female and male monkeys.
Allen M, Johnson B, Kumar A, Su Y, Singh S, Deep G
Addict Neurosci. 2024; 11.
PMID: 38911873
PMC: 11192513.
DOI: 10.1016/j.addicn.2024.100151.
Community-led approaches to making naloxone available in public settings: Implementation experiences in the HEALing communities study.
Starbird L, Onuoha E, Corry G, Hotchkiss J, Benjamin S, Hunt T
Int J Drug Policy. 2024; 128:104462.
PMID: 38795466
PMC: 11213655.
DOI: 10.1016/j.drugpo.2024.104462.
Federal Impacts on Buprenorphine Prescribing in Washington State, 2012 to 2022.
Xiong F, Jetson J, Park C, Delcher C
Am J Public Health. 2024; 114(7):696-704.
PMID: 38696736
PMC: 11153960.
DOI: 10.2105/AJPH.2024.307649.
Machine Learned Classification of Ligand Intrinsic Activities at Human -Opioid Receptor.
Oh M, Shen M, Liu R, Stavitskaya L, Shen J
bioRxiv. 2024; .
PMID: 38645122
PMC: 11030315.
DOI: 10.1101/2024.04.07.588485.
Frontline Perspectives on Buprenorphine for the Management of Chronic Pain.
Adler J, Mallick-Searle T, Garofoli M, Zimmerman A
J Multidiscip Healthc. 2024; 17:1375-1383.
PMID: 38563040
PMC: 10982663.
DOI: 10.2147/JMDH.S449748.
Clinical risk prediction using language models: benefits and considerations.
Acharya A, Shrestha S, Chen A, Conte J, Avramovic S, Sikdar S
J Am Med Inform Assoc. 2024; 31(9):1856-1864.
PMID: 38412328
PMC: 11339498.
DOI: 10.1093/jamia/ocae030.
Identification of Myths and Misinformation About Treatment for Opioid Use Disorder on Social Media: Infodemiology Study.
ElSherief M, Sumner S, Krishnasamy V, Jones C, Law R, Kacha-Ochana A
JMIR Form Res. 2024; 8:e44726.
PMID: 38393772
PMC: 10924265.
DOI: 10.2196/44726.
How Does Medicaid Managed Care Address the Needs of Beneficiaries with Opioid Use Disorders? A Deep Dive into Contract Design.
Morris R, Rosenbaum S, Grogan C, Rhodes M, Andrews C
Am J Law Med. 2024; 49(2-3):339-348.
PMID: 38344786
PMC: 11185417.
DOI: 10.1017/amj.2023.35.